Nick joined AgonOx at its inception in 2011 to lead the design of new therapeutics and to develop new in vitro functional assays.  His previous work at the Earle A. Chiles Cancer Center at Providence Portland Medical Center began in 2001 where he used his background in protein biochemistry and structure to lead the development of OX40 agonist antibodies and recombinant proteins.

His preclinical work helped to initiate the first anti-OX40 clinical trial in patients with cancer.